ROSEMONT PHARMACEUTICALS LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. ROSEMONT PHARMACEUTICALS LIMITED 1994-08-10 → present
2. R. P. DRUGS LIMITED 1967-12-14 → 1994-08-10

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis which assumes that the Company will continue in operational existence for the foreseeable future and meet its liabilities as they fall due.”

Group structure

1. ROSEMONT PHARMACEUTICALS LIMITED · parent
   1. Rosemont Pharma Liquids Limited 100% · England
   2. Rosemont Pharmaceuticals Holdings Inc 100% · GA
   3. Lucis Holdings Limited 100% · England
   4. Lucis Pharma Ltd 100% · England
   5. Pharmadata S.A 100% · Greece
   6. Sabal Therapeutics LLC 100% · GA
   7. Rosemont Pharmaceuticals LLC 100% · GA
   8. Palmetto Pharmaceuticals, INC 100% · GA
   9. Athena Bioscience LLC 100% · GA
   10. Sarras Health LLC 100% · GB

Significant events

• “During the year the Company, and its wider group concluded a group reorganisation exercise to simplify its Corporate structure and align to its operational and future strategic goals.”
• “The Company continued with strong sales performance in 2025 with recorded turnover of £121.1m (2024 - £114.6m), representing growth of £6.5m (5.7%).”
• “launch of two new products during the year.”
• “successfully completed several in-licensing agreements during the year increasing its portfolio, geographic and patient reach.”
• “one off exceptional items in the year related to the Group reorganisation exercise and write offs on certain intangible assets”
• “The Group completed a full refinancing of its existing debt facilities in the year achieving a reduction in the overall margins applicable reducing from 7.5% to 5% plus SONIA on its senior debt facilities and providing funding to the Company and the wider group until 2032. With uncertainty still over the UK interest rates and inflation figures as part of the refinancing the group also restructured and extended out its existing hedging arrangement, putting in place a new cap/collar arrangement over all drawn debt facilities until December 2028.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

16

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +5.7%

  £114,551,000 → £121,088,000

• Cash

  +5.4%

  £10,670,000 → £11,250,000

• Net assets

  -5.1%

  £169,217,000 → £160,533,000

• Employees

  +9.7%

  258 → 283

• Operating profit

  -14.7%

  £42,441,000 → £36,192,000

• Profit before tax

  -12.4%

  £46,213,000 → £40,498,000

• Wages

  +20.1%

  £13,820,000 → £16,595,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers